骨髄異形成症候群（MDS）治療薬の世界市場レポート 2025年

骨髄異形成症候群（MDS）治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.2％で51億2,000万米ドルに成長します。予測期間の成長は、ゲノム研究、免疫療法、ヘルスケアの世界的拡大、バイオマーカー同定に起因しています。予測期間における主な動向には、個別化医療、併用療法、症状管理、データ共有、コラボレーションなどがあります。

化学療法や放射線療法などのがん治療への曝露の増加は、今後数年間の骨髄異形成症候群（MDS）治療薬市場の拡大を刺激すると予想されます。化学療法はがん細胞を除去するために薬剤を使用し、放射線療法はがん細胞を標的として腫瘍を縮小させるために高線量の放射線を使用します。化学療法薬も放射線治療も、新しい血液細胞の生成に重要な役割を果たす骨髄の幹細胞に悪影響を及ぼす可能性があります。このような正常な細胞産生の障害は、MDSの発症につながる可能性があります。骨髄異形成症候群（MDS）治療薬は、骨髄での異常な血球産生を特徴とする疾患群であるMDSの管理および治療において、様々な利点を提供します。例えば、欧州放射線腫瘍学会（ESTRO）は、予測されるがん分布に基づき、2025年までに放射線治療数が16％増加すると推定しています。その結果、化学療法や放射線を含むがん治療への被曝量の増加が、骨髄異形成症候群（MDS）治療薬市場の成長の原動力となっています。

骨髄性白血病患者の急増は、骨髄異形成症候群（MDS）薬物治療市場の拡大を促進すると予測されています。骨髄性白血病は骨髄に発生するがんの一種で、様々な種類の血液細胞を生成する細胞に影響を与えます。骨髄異形成症候群（MDS）治療薬は、白血病の根本原因に対処することで骨髄機能を高め、血球数減少に伴う合併症のリスクを低減し、化学療法や移植の必要性を減らし、最終的には骨髄異形成症候群（MDS）患者の生存率を改善することを目指しています。例えば、米国がん学会は、2023年には成人における急性骨髄性白血病（AML）の患者数は約20,380人、死亡者数は約11,310人になると推定しています。その結果、骨髄性白血病の罹患率の増加が、骨髄異形成症候群（MDS）治療薬市場の成長を支える重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の骨髄異形成症候群（MDS）治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の骨髄異形成症候群（MDS）治療薬市場：成長率分析
• 世界の骨髄異形成症候群（MDS）治療薬市場の実績：規模と成長、2019～2024年
• 世界の骨髄異形成症候群（MDS）治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の骨髄異形成症候群（MDS）治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨髄異形成症候群（MDS）治療薬市場：薬の種類別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法
• 免疫調節薬
• 世界の骨髄異形成症候群（MDS）治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• 世界の骨髄異形成症候群（MDS）治療薬市場：症候群別、実績と予測、2019～2024年、2024～2029年、2034年
• 多系統異形成を伴う難治性血球減少症
• 不応性貧血
• 環状鉄芽球を伴う難治性貧血
• 世界の骨髄異形成症候群（MDS）治療薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 外来手術センター
• 世界の骨髄異形成症候群（MDS）治療薬市場：化学療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 低メチル化剤
• 細胞毒性剤
• 世界の骨髄異形成症候群（MDS）治療薬市場：免疫調節薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• レナリドミド
• サリドマイド
• ポマリドミド

第7章 地域別・国別分析

• 世界の骨髄異形成症候群（MDS）治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の骨髄異形成症候群（MDS）治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨髄異形成症候群（MDS）治療薬市場：競合情勢
• 骨髄異形成症候群（MDS）治療薬市場：企業プロファイル
  • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Mylan NV Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Cipla Limited
• Acceleron Pharma Inc.
• Aprea Therapeutics
• Onconova Therapeutics Inc.
• Geron Corporation
• Amgen Inc.
• Sandoz
• Gilead Sciences Inc.
• Johnson And Johnson
• Lupin Ltd. Corporation
• Ono Pharmaceutical Co. Ltd.
• Eisai Co. Ltd.
• Nippon Shinyaku Co. Ltd.
• Lupin Ltd.
• Accord Healthcare Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨髄異形成症候群（MDS）治療薬市場2029：新たな機会を提供する国
• 骨髄異形成症候群（MDS）治療薬市場2029：新たな機会を提供するセグメント
• 骨髄異形成症候群（MDS）治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myelodysplastic syndrome (MDS) drugs are pharmaceuticals utilized in the treatment of myelodysplastic syndrome, a group of bone marrow disorders characterized by insufficient production of healthy blood cells. These drugs operate by facilitating the restoration of normal gene function in bone marrow cells, leading to increased red blood cell production.

The primary categories of drugs used for myelodysplastic syndrome (MDS) treatment include chemotherapy and immunomodulatory drugs. Chemotherapy is a cancer treatment approach that employs anti-cancer medications to eliminate cancerous cells. These drugs can be administered via oral or parenteral routes to manage conditions such as refractory cytopenia with multilineage dysplasia, refractory anemia, and refractory anemia with ringed sideroblasts. Various healthcare settings, including hospitals, clinics, and ambulatory surgical centers, are involved in the distribution and administration of these drugs.

The myelodysplastic syndrome (MDS) drugs market research report is one of a series of new reports from The Business Research Company that provides myelodysplastic syndrome (MDS) drugs market statistics, including myelodysplastic syndrome (MDS) drugs industry global market size, regional shares, competitors with a myelodysplastic syndrome (MDS) drugs market share, detailed myelodysplastic syndrome (MDS) drugs market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome (MDS) drugs industry. This myelodysplastic syndrome (MDS) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myelodysplastic syndrome (MDS) drugs market size has grown strongly in recent years. It will grow from $3.47 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, advancements in targeted therapies, clinical trials, increased awareness.

The myelodysplastic syndrome (MDS) drugs market size is expected to see strong growth in the next few years. It will grow to $5.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to genomic research, immunotherapies, global expansion of healthcare, biomarker identification. Major trends in the forecast period include personalized medicine, combinatorial therapies, symptom management, data sharing and collaboration.

The growing exposure to cancer treatments, such as chemotherapy and radiation, is expected to stimulate the expansion of the myelodysplastic syndrome (MDS) drug market in the coming years. Chemotherapy involves the use of medications to eliminate cancer cells, while radiation therapy employs high doses of radiation to target cancer cells and reduce tumor sizes. Both chemotherapy drugs and radiation treatments can negatively affect the bone marrow's stem cells, which play a crucial role in generating new blood cells. This disruption in normal cell production can lead to the development of MDS. Myelodysplastic syndrome (MDS) drugs offer various benefits in managing and treating MDS, a group of disorders characterized by abnormal blood cell production in the bone marrow. For instance, the European Society of Radiation Oncology (ESTRO) estimates that there will be a 16% increase in the number of radiotherapy treatment courses by 2025 based on projected cancer distributions. Consequently, the rising exposure to cancer treatments, including chemotherapy and radiation, is a driving force behind the growth of the myelodysplastic syndrome (MDS) drugs market.

The surge in myeloid leukemia cases is projected to advance the expansion of the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia is a type of cancer originating in the bone marrow, impacting the cells responsible for generating various blood cell types. Myelodysplastic syndrome (MDS) drugs aim to enhance bone marrow function by addressing the root causes of leukemia, thereby reducing the risk of complications associated with low blood cell counts, decreasing the necessity for chemotherapy and transplants, and ultimately improving survival rates for individuals with myelodysplastic syndrome (MDS). For example, the American Cancer Society estimates that there will be around 20,380 cases and 11,310 deaths in adults from acute myeloid leukemia (AML) in 2023. Consequently, the increasing incidence of myeloid leukemia is a key driver behind the myelodysplastic syndrome (MDS) drug market's growth.

Leading companies in the myelodysplastic syndrome (MDS) drugs market are concentrating on the development of new products, such as targeted therapies, to enhance patient outcomes, address specific customer needs, and integrate into the medical ecosystem. Targeted therapy for MDS involves drugs that precisely address genetic mutations or molecular irregularities in cancer cells, with the goal of improving outcomes by focusing on abnormal cells while reducing harm to healthy tissue. For example, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for treating adult patients with relapsed or refractory (R/R) MDS with an isocitrate dehydrogenase-1 (IDH1) mutation. This approval was based on the effectiveness of Tibsovo in an open-label, single-arm, multicenter study involving 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.

In April 2022, GlaxoSmithKline plc, a focused biopharmaceutical company, acquired Sierra Oncology, Inc. for $1.9 billion. This acquisition supports GSK's broader strategy to strengthen its portfolio of specialty medicines and vaccines, with a focus on oncology and addressing unmet needs within the rare disease patient population. Sierra Oncology, Inc. is a U.S.-based biopharmaceutical company specializing in targeted therapies for treating rare cancers and myelodysplastic syndrome (MDS).

Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.

North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelodysplastic syndrome (MDS) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelodysplastic syndrome (MDS) drugs market consists of sales of vidaza (azacitidine), dacogen (decitabine) and reblozyl (luspatercept-aamt). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelodysplastic syndrome (mds) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelodysplastic syndrome (mds) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myelodysplastic syndrome (mds) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Chemotherapy; Immunomodulatory Drugs
• 2) By Route Of Administration: Oral; Parenteral
• 3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia; Refractory Anemia; Refractory Anemia With Ringed Sideroblasts
• 4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Chemotherapy: Hypomethylating Agents; Cytotoxic Agents
• 2) By Immunomodulatory Drugs: Lenalidomide; Thalidomide; Pomalidomide
• Companies Mentioned: Bristol Myers Squibb; Otsuka Pharmaceutical Co. Ltd.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Mylan NV
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myelodysplastic Syndrome (MDS) Drugs Market Characteristics

3. Myelodysplastic Syndrome (MDS) Drugs Market Trends And Strategies

4. Myelodysplastic Syndrome (MDS) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Myelodysplastic Syndrome (MDS) Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myelodysplastic Syndrome (MDS) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myelodysplastic Syndrome (MDS) Drugs Market Growth Rate Analysis
• 5.4. Global Myelodysplastic Syndrome (MDS) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myelodysplastic Syndrome (MDS) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myelodysplastic Syndrome (MDS) Drugs Total Addressable Market (TAM)

6. Myelodysplastic Syndrome (MDS) Drugs Market Segmentation

• 6.1. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunomodulatory Drugs
• 6.2. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.3. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Refractory Cytopenia With Multilineage Dysplasia
• Refractory Anemia
• Refractory Anemia With Ringed Sideroblasts
• 6.4. Global Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• 6.5. Global Myelodysplastic Syndrome (MDS) Drugs Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypomethylating Agents
• Cytotoxic Agents
• 6.6. Global Myelodysplastic Syndrome (MDS) Drugs Market, Sub-Segmentation Of Immunomodulatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lenalidomide
• Thalidomide
• Pomalidomide

7. Myelodysplastic Syndrome (MDS) Drugs Market Regional And Country Analysis

• 7.1. Global Myelodysplastic Syndrome (MDS) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myelodysplastic Syndrome (MDS) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market

• 8.1. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myelodysplastic Syndrome (MDS) Drugs Market

• 9.1. China Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 9.2. China Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myelodysplastic Syndrome (MDS) Drugs Market

• 10.1. India Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myelodysplastic Syndrome (MDS) Drugs Market

• 11.1. Japan Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 11.2. Japan Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myelodysplastic Syndrome (MDS) Drugs Market

• 12.1. Australia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market

• 13.1. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myelodysplastic Syndrome (MDS) Drugs Market

• 14.1. South Korea Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 14.2. South Korea Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market

• 15.1. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 15.2. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myelodysplastic Syndrome (MDS) Drugs Market

• 16.1. UK Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myelodysplastic Syndrome (MDS) Drugs Market

• 17.1. Germany Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myelodysplastic Syndrome (MDS) Drugs Market

• 18.1. France Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myelodysplastic Syndrome (MDS) Drugs Market

• 19.1. Italy Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myelodysplastic Syndrome (MDS) Drugs Market

• 20.1. Spain Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market

• 21.1. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 21.2. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myelodysplastic Syndrome (MDS) Drugs Market

• 22.1. Russia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myelodysplastic Syndrome (MDS) Drugs Market

• 23.1. North America Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 23.2. North America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myelodysplastic Syndrome (MDS) Drugs Market

• 24.1. USA Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 24.2. USA Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myelodysplastic Syndrome (MDS) Drugs Market

• 25.1. Canada Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 25.2. Canada Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myelodysplastic Syndrome (MDS) Drugs Market

• 26.1. South America Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 26.2. South America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myelodysplastic Syndrome (MDS) Drugs Market

• 27.1. Brazil Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myelodysplastic Syndrome (MDS) Drugs Market

• 28.1. Middle East Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 28.2. Middle East Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myelodysplastic Syndrome (MDS) Drugs Market

• 29.1. Africa Myelodysplastic Syndrome (MDS) Drugs Market Overview
• 29.2. Africa Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myelodysplastic Syndrome (MDS) Drugs Market, Segmentation By Syndrome, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myelodysplastic Syndrome (MDS) Drugs Market Competitive Landscape And Company Profiles

• 30.1. Myelodysplastic Syndrome (MDS) Drugs Market Competitive Landscape
• 30.2. Myelodysplastic Syndrome (MDS) Drugs Market Company Profiles
  • 30.2.1. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mylan NV Overview, Products and Services, Strategy and Financial Analysis

31. Myelodysplastic Syndrome (MDS) Drugs Market Other Major And Innovative Companies

• 31.1. Cipla Limited
• 31.2. Acceleron Pharma Inc.
• 31.3. Aprea Therapeutics
• 31.4. Onconova Therapeutics Inc.
• 31.5. Geron Corporation
• 31.6. Amgen Inc.
• 31.7. Sandoz
• 31.8. Gilead Sciences Inc.
• 31.9. Johnson And Johnson
• 31.10. Lupin Ltd. Corporation
• 31.11. Ono Pharmaceutical Co. Ltd.
• 31.12. Eisai Co. Ltd.
• 31.13. Nippon Shinyaku Co. Ltd.
• 31.14. Lupin Ltd.
• 31.15. Accord Healthcare Inc.

32. Global Myelodysplastic Syndrome (MDS) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myelodysplastic Syndrome (MDS) Drugs Market

34. Recent Developments In The Myelodysplastic Syndrome (MDS) Drugs Market

35. Myelodysplastic Syndrome (MDS) Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Myelodysplastic Syndrome (MDS) Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myelodysplastic Syndrome (MDS) Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myelodysplastic Syndrome (MDS) Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer